Search

Displaying results 4611 - 4620 of 10000 in total
  1. Drug

    Butenafine

    go.drugbank.com/drugs/DB01091
    Approved

    In particular, butenafine acts to inhibit the activity of the squalene epoxidase enzyme that is essential in the formation of sterols necessary for fungal cell membranes.

    Synonyms: (4-tert-butylphenyl)-N-methyl-N-(naphthalen-1-ylmethyl)methanamine, N-(p-tert-butylbenzyl)-N-methyl-1-naphthalenemethylamine
  2. Drug

    GI-181771X

    go.drugbank.com/drugs/DB12309
    Experimental

    Gski181771 X is under investigation in clinical trial NCT00600743 (Effect of a CCK-1R Agonist on Food Intake in Humans).

  3. Drug

    NBI-6024

    go.drugbank.com/drugs/DB05819
    Investigational

    NBI-6024 is an altered peptide ligand that is designed to cause an immune response which result in preservation of beta-cell function and endogenous insulin production.

  4. Drug

    Setrusumab

    go.drugbank.com/drugs/DB14778
    Investigational

    Setrusumab is under investigation in clinical trial NCT01406548 (Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density).

  5. Drug

    Alovudine F-18

    go.drugbank.com/drugs/DB14930
    Investigational

    Alovudine F-18 is under investigation in clinical trial NCT02819024 (Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography).

  6. Drug

    Viagenpumatucel-L

    go.drugbank.com/drugs/DB16348
    Investigational

    Viagenpumatucel-L is under investigation in clinical trial NCT02117024 (A Phase 2 Study of Viagenpumatucel-l (HS-110) in Patients With Non-small Cell Lung Cancer).

  7. Drug

    KUR-113

    go.drugbank.com/drugs/DB18413
    Investigational

    KUR-113 is an investigational fibrin-based agent containing an N-terminally modified parathyroid hormone fragment. It is being investigated as a bioactive bone graft substitute.

    Synonyms: Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGplPTH1-34
  8. Drug

    Finafloxacin

    go.drugbank.com/drugs/DB09047
    ApprovedWithdrawn

    Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.

  9. Drug

    Sizofiran

    go.drugbank.com/drugs/DB13128
    Investigational

    It is used as an immunoadjuvant in the treatment of neoplasms, especially tumors found in the stomach. Sizofiran has been used in trials studying the treatment of Cervical Cancer.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    SAR443122

    go.drugbank.com/drugs/DB16492
    Investigational

    Additionally, NCT04781816, which was completed with results, focused on patients with cutaneous lupus erythematosus. … SAR443122, was investigated in several clinical trials to evaluate its safety and efficacy.

    Synonyms: 1H-1,2,4-TRIAZOLE-5-CARBOXAMIDE, 3-(PHENYLMETHYL)-N-((3S)-2,3,4,5-TETRAHYDRO-5-METHYL-4-OXOPYRIDO(3,2-B)(1,4)OXAZEPIN-3-YL)-, 3-(PHENYLMETHYL)-N-((3S)-2,3,4,5-TETRAHYDRO-5-METHYL-4-OXOPYRIDO(3,2-B)(1,4)OXAZEPIN-3-YL)-1H-1,2,4-TRIAZOLE-5-CARBOXAMIDE